- Home
- AIRS vs CELC Comparison
AIRS vs CELC Comparison
Compare AIRS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- CELC
- Stock Information
- Founded
- AIRS 2012
- CELC 2011
- Country
- AIRS United States
- CELC United States
- Employees
- AIRS N/A
- CELC N/A
- Industry
- AIRS Medical/Nursing Services
- CELC Medical Specialities
- Sector
- AIRS Health Care
- CELC Health Care
- Exchange
- AIRS Nasdaq
- CELC Nasdaq
- Market Cap
- AIRS 333.7M
- CELC 391.0M
- IPO Year
- AIRS 2021
- CELC 2017
- Fundamental
- Price
- AIRS $2.15
- CELC $9.39
- Analyst Decision
- AIRS Hold
- CELC Strong Buy
- Analyst Count
- AIRS 3
- CELC 6
- Target Price
- AIRS $3.75
- CELC $30.17
- AVG Volume (30 Days)
- AIRS 374.4K
- CELC 248.4K
- Earning Date
- AIRS 03-14-2025
- CELC 03-31-2025
- Dividend Yield
- AIRS N/A
- CELC N/A
- EPS Growth
- AIRS N/A
- CELC N/A
- EPS
- AIRS N/A
- CELC N/A
- Revenue
- AIRS $180,350,000.00
- CELC N/A
- Revenue This Year
- AIRS N/A
- CELC $49.98
- Revenue Next Year
- AIRS $5.63
- CELC N/A
- P/E Ratio
- AIRS N/A
- CELC N/A
- Revenue Growth
- AIRS N/A
- CELC N/A
- 52 Week Low
- AIRS $2.05
- CELC $8.53
- 52 Week High
- AIRS $9.20
- CELC $22.04
- Technical
- Relative Strength Index (RSI)
- AIRS 27.39
- CELC 40.19
- Support Level
- AIRS $2.58
- CELC $9.98
- Resistance Level
- AIRS $2.91
- CELC $10.91
- Average True Range (ATR)
- AIRS 0.33
- CELC 0.66
- MACD
- AIRS 0.01
- CELC 0.02
- Stochastic Oscillator
- AIRS 19.33
- CELC 12.74
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.